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16METHODOLOGY Open AccessCompensability index for compensation
radiotherapy after treatment interruptions
Paul Martin Putora1*, Michael Schmuecking2, Daniel Aebersold2 and Ludwig Plasswilm1Abstract
Background: The goal of our work was to develop a simple method to evaluate a compensation treatment after
unplanned treatment interruptions with respect to their tumour- and normal tissue effect.
Methods: We developed a software tool in java programming language based on existing recommendations to
compensate for treatment interruptions. In order to express and visualize the deviations from the originally planned
tumour and normal tissue effects we defined the compensability index.
Results: The compensability index represents an evaluation of the suitability of compensatory radiotherapy in a
single number based on the number of days used for compensation and the preference of preserving the originally
planned tumour effect or not exceeding the originally planned normal tissue effect. An automated tool provides a
method for quick evaluation of compensation treatments.
Conclusions: The compensability index calculation may serve as a decision support system based on existing and
established recommendations.
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Radiation oncology plays a central role in the treatment of
many cancers [1]. The basis of this treatment lies in the
different susceptibility and repair capacity of tumour and
normal tissues [2]. Radiobiological factors influencing the
resistance of cancers to radiotherapy treatment include
among others: repopulation, re-oxygenation, repair of
sub–lethal damage and re-assortment of cells within the
cell cycle [3].
Although several models to estimate and calculate the
effect of radiotherapy in cancer as well as normal tissues,
including acute and late effects, have been proposed, the
alpha-beta model has found widest acceptance in clinical
routine [4-6]. Even though most models do not account for
the full complexity of interactions as they are known today,
available practical models rely on the alpha-beta model and
may include a factor that is to account for repopulation.
The estimates of repopulation as well as alpha/beta values
differ between tumour types and any prediction derived* Correspondence: Paul.Putora@kssg.ch
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reproduction in any medium, provided the orfrom these results is less precise than the data they are
based on [7,8].
A practical procedure has been proposed by the Royal
College of Radiologists. This was chosen as a basis for our
calculations. Within their recommendation the repopula-
tion in head and neck cancer is compensated for by
subtracting 0.9Gy per treatment day starting after the 4th
week [9]. Of course this is a simplified model and cannot
account for every inter- and intra- tumour variability,
feasible ranges are most likely from 0.5-0.9Gy [10]. Of
course the same uncertainty applies to the 4th week [11,12].
The values are very much dependent on the tumour
histology.
Treatment breaks due to technical problems, organisa-
tional or patient-related issues, holidays or even side effects
of treatment may arise. These treatment interruptions are
usually not accounted for sufficiently when treatment is
simply continued with the originally planned fractionation.
If a sub-optimal compensatory regime is chosen the
tumour control rate may be jeopardized or unacceptable
side effects risked.
Radiation oncologists are often confronted with the
decision to adapt a radiotherapy regime when unsched-
uled interruptions take place. The decision may be toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Aggressivity ranges from defensive to offensive
compensation.
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dose per fraction of the remaining fractions or changing
both, or even the timing (e.g. twice daily treatments). De-
pending on the clinical scenario, not adapting a radiother-
apy regime and accepting deviations may also be an option.
Increasing the total dose (by increasing the number of
fractions or increasing the dose per fraction) to adapt to
the same expected tumour control rate may not always
be the best solution.Many treatment regimens are deter-
mined and limited by the possible acute or late side
effects. By increasing the dose to compensate for treat-
ment brakes one might increase the risk for side effects
on normal tissues.
When established regimes are changed, the available data
guiding our decisions becomes thinner. This is why a solid
justification is required for tampering with established
radiotherapy regimes.
When a compensatory treatment is calculated to correct
for the effect on tumour tissue, it is necessary to recalculate
the effect on normal tissues as well [9]. The clinician is then
faced with two factors in his decision: the new tumour
biologically effective dose (ideally approaching the originally
planned effect against the tumour) and the biologically
effective dose to organs at risk (representing the risk for
side effects), especially the late side effects probability.
Ideally the compensating treatment should not increase the
risk for normal tissue complications.
Materials and methods
For a given number of days to compensate there are
two extremes:
Offensive compensation
The compensating treatment is defined in such a way as
to achieve the same effect in the tumor tissue: i.e. 100% of
the original dose.
Defensive compensation
The other extreme is defining the compensatory treatment
in such a way as to avoid increasing risk to normal tissues,
i.e. the late normal tissues complication probability remains
the same as in the initially planned treatment. This might
be of interest in plans that are designed based on the dose
constraints of critical organs, such as the brainstem or optic
chiasm for example.
The aggressivity of a compensated treatment plan will
be judged differently in palliative or curative intention.
One always needs to keep in mind that there are limita-
tions in the values used, which are based on estimates.
Aggressivity
We term the axis from defensive to offensive compensation
aggressivity (see Figure 1).Simple calculators, including sliders, may be used to
find a clinically acceptable compromise between offensive
and defensive treatment compensation [13], an example
of a smartphone based program is shown in Figure 2.
In the example in Figure 2 the aggressivity of treatment
can be chosen based on the relative effect of the new dose
per fraction on tumour as well as late effects. For typical
calculations the alpha/beta ratio for tumour tissue is 10,
and for normal tissue late effects: 3. The optimal compen-
sation treatment depends on dose per fraction and number
of additional treatments.
The optimal compensation treatment needs to be
searched for in two dimensions: aggressivity as well as the
number of days used for compensation (Figure 3).
We developed a java based compensation treatment
calculator calculating tumour as well as normal tissue
doses based mostly on the calculations proposed by the
Royal College of Radiologists [9].
Input into the model includes: Parameters of the
planned treatment:
– The planned number of fractions
– The planned dose per fraction
– The planned duration of treatment (the planned
number of fractions + e.g. planned weekend brakes)
Parameters of the planned treatment:
– The applied number of fractions
– The applied dose per fraction
– The duration of the applied treatment (up to the
treatment brake)
Duration of the treatment brake.
Radiobiological parameters specific for tumour and
normal tissue
– The factor in Gy by which repopulation is
accounted for (starting with day 29)
– The alpha/beta value for the tumour
– The alpha/beta value for late normal tissue effects
A sample calculation is shown in Figure 4. A head&neck
cancer patient received only 30 of 35 planned fractions of
2Gy in the originally planned time period (46days). In this
Figure 2 A radiotherapy treatment compensation calculator.
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ment interruption. For each day beyond the 4th week of
treatment, the effective tumour dose is reduced by 0.9 Gy
per day. The BED10planned represents the biologically
equivalent dose (BED) that was intended to be delivered
to the tumour. The BED3planned represents the effect on
normal tissue. The applied dose is represented by
BED10applied and BED3applied respectively. To achieve
the same tumour effect a total tumour BED of 67.8Gy is
required (the same value as the BED10planned). A loss ofFigure 3 The optimal compensation treatment needs to be
found on a 2 dimensional plane consisting of aggressivity and
duration (days available for compensatory treatment).0.9Gy per day after the 4th week is subtracted (including
the 5 days of treatment prolongation due to compensatory
treatment). When the formula is solved a dose per fraction
of 2.62Gy is obtained. The BED3new is calculated using this
dose per fraction and a new BED value for normal tissue is
determined. The BED3ratio represents the ratio between
BED3new and BED3original, in this case 106.7%. In this
example the compensation treatment was calculated to
maintain the originally planned tumour dose leading to a
BED10ratio of 100%.
Every proposed compensation treatment results in two
important values: the new tumour dose as well as the new
late effects dose, each expressed in percent compared to
the initially planned treatment.
In the example in Figure 4 the tumour dose would be
100%, the late effects dose would be 106.7%. Due to the
nature of the sigmoid shapes of the dose response curves
larger deviations from the planned treatment will probably
result in over-proportional deviations in results.
We assumed it would be logical to search for a com-
promise between offensive and defensive treatments
where both values are close to 100%. The goal should be
to keep the sum of the squares of the deviations as low as
possible. This value we termed the compensability index:
Compensability Index ¼ 1 new tumor effect
planned tumor effect
 2
þ new normal tissue effect
planned normal tissue effect
 1
 2
When the treatment can be compensated for with the
same tumour and late effect the compensability index is 0,
Figure 4 Calculating the late effect dose in percent from the compensation treatment for maximum compensation of tumour effect
(offensive extreme), the tumor BED is 100% resulting in an increase of the normal tissue BED by 6.7%.
Figure 5 The calculated compensation doses for the given
head&neck cancer example are displayed. The y axis represents
the number of days used for compensation, the x axis represents
the level of aggressivity (from defensive on the left to offensive on
the right).
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increases with the sum of square powers of the deviations.
The square power was chosen for weighting the devia-
tions as the effect would be expected to be exponential.
This too is a simplification as the change in effect is also
dependent on the position within the sigmoid curve.
However as these details are not available for individual
patients we believe the square power represents a useful
practical solution.
Results
An automated java tool has shown to be a very efficient
method of displaying all compensation options in a two-
dimensional plane. Figure 5 shows the calculated doses for
the given head&neck example.
The doses per fraction are displayed in green when they
are the same or less, they turn to red as the doses per
fraction increase.
The compensability index can also be displayed on the
same matrix (Figure 6).
The matrix displayed in Figure 6 provides an overview
of the resulting compensability indices for various combi-
nations of aggressivity and duration. On the horizontal
axis the aggressivity ranges from 0% on the left to 100%
on the right. The vertical axis represents the duration of
the compensatory treatment with 1 day on the top and 10
days on the bottom. For each combination the compensa-
tory index is calculated and displayed. Lower compensabi-
lity indices (suitable) are displayed in green, the higher
(less suitable) are displayed in red. The gradual change in
colour also demonstrates that there are several solutions
to the problem with similar results.Discussion
The compensability index provides a visualization method
for a very complex set of information. It allows for an
overview for many compensation variations (e.g. 100) at
one glance. Foremost, the compensability index may help
in quick orientation quiding the physician to the optimal
combination of compensatory treatment days and dose
per fraction.
Figure 6 The compensability index displayed on a plane with
the y axis representing the number of days for compensation
and the x axis the aggressivity.
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basic model. Concurrent chemotherapy, alternate fractio-
nations, twice or thrice daily radiation and existing side
effects are not considered currently in this concept. Ad-
ditionally, the tolerance of several organs may be limiting
for treatment and cannot be ignored. Other modalities
such as pulse-, high- or low dose rate brachytherapy, single
fraction radiotherapy or combinations of modalities are
not dealt with. We believe, despite these limitations, that
the compensability index may be expanded to include
these topics in the future.
Depending on the clinical details; deviations from the
planned tumour or normal tissue effects can be acceptedFigure 7 Sample interface of a compensability index calculator.without compensation. The basis of these calculations
are assumed alpha/beta values, the result of the pre-
sented calculations is only as reliable as the alpha/beta
estimates of normal and tumour tissues and the
alpha/beta model itself.
The described calculations also do not account for
individual patient characteristics, previous treatments,
concurrent chemotherapy and details of dose distribu-
tion. As the compensability index does not account for
the specifics of a treatment or the patient, the clinician
will always have to decide on a case-to-case basis.
Any change from an established regime may be asso-
ciated with increased risks, this deviation needs to be
justified and the risks considered. The compensability
index is not a justification for any clinical decision per
se, but may serve as a decision support system.
With all the known limitations the concept pro-
vides a method to quickly recalculate values on
which most of our treatments are based. Graphical
representation of the results also has an educational
character as the effect of input parameters can be
easily visualized (Figures 5–7).Conclusions
The compensability index provides an efficient way to
recalculate the tumour and normal tissue effects based on
established and recommended formulas. A calculator-tool
can be used as a decision support system, but does not
replace clinical judgement. Before changing any treatment
schedule a review of the treatment plan of each individual
patient is mandatory.
The authors would welcome any collaboration on
extending the compensability index and are happy to
provide the current version for testing upon request.
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